Role of Histaminergic System in Blood-Brain Barrier Dysfunction Associated with Neurological Disorders

Archives of Medical Research

Volumn 45, Issue 8, 2014, Pages 677-686

  Bañuelos Cabrera, Ivette ^a   Valle Dorado, María Guadalupe ^a   Aldana, Blanca Irene ^a   Orozco Suárez, Sandra Adela ^b   Rocha, Luisa ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b Century XXI   (Mexico)

Author keywords

Blood brain barrier; Histamine; Mast cells; Neuroinflammation; Neurological disorders

Indexed keywords

ANTIHISTAMINIC AGENT; CELECOXIB; CYTOKINE; DIAZEPAM; FINGOLIMOD; GUANYLATE KINASE; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; HISTAMINE RELEASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; LIDOCAINE; MASTINIB; MEMBRANE PROTEIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NERVE GROWTH FACTOR; PROTEIN ZO1; PROTEIN ZO2; SODIUM CHANNEL; SUBSTANCE P; TRANSCRIPTION FACTOR; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANXIETY; BEHAVIOR CHANGE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN NERVE CELL; BRAIN REGION; BRAIN TUMOR; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; DEPRESSION; DOPAMINERGIC SYSTEM; ENCEPHALITIS; ENDOTHELIUM CELL; EOSINOPHIL; EPILEPSY; EPILEPTOGENESIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GLIA CELL; GLIOMA; HISTAMINE RELEASE; HUMAN; LEUKOCYTE; LYMPHOCYTE; MAST CELL; MASTOCYTOSIS; MEDIATOR RELEASE; MEMBRANE DAMAGE; METASTASIS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUTROPHIL; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC MEMBRANE; REVIEW; SYNAPTIC TRANSMISSION; TIGHT JUNCTION; TUMOR GROWTH; BIOSYNTHESIS; INFLAMMATION; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; BLOOD-BRAIN BARRIER; EPILEPSY; HISTAMINE; HUMANS; INFLAMMATION; MAST CELLS; PARKINSON DISEASE;

EID: 84924812512     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.11.010     Document Type: Review

References (159)

1. Dale H.H., Laidlaw P.P. The physiological action of imidiazolethyl-amina. J Physiol 1910, 41:318-344.
2. Popielski L. b-Imidazolylathylamin und die Organextrakte Erster Teil: b-Imidazolylathylamin als mechtiger Errezer der Magendrucken. Pfluegers Arch 1920, 178:214-236.
3. Kwiatkowski H. Observations on the relation of histamine to reactive hyperaemia. J Physiol 1941, 100:147-158.
4. White T. Formation and catabolism of histamine in brain tissue invitro. J Physiol 1959, 149:34-42.
5. Peter D., Liu Y., Sternini C., et al. Differential expression of two vesicular monoamine transporter. J Neurosci 1995, 15:6179-6188.
6. Verdiere M., Rose C., Schwartz J.C. "Synthesis and release of histamine studied on slices from rat hypothalamus". Eur J Pharmacol 1975, 34:157-168.
7. Ogasawara M., Yamauchi K., Satoh Y., et al. Organic cation transporters as a histamine transporter and histamine metabolism. Recent advances in molecular pharmacology of the histamine systems. J Pharm Sci 2006, 30:24-30.
8. Panula P., Yang H.Y., Costa E. Histamine-containing neurons in the rat hypothalamus. PNAS 1984, 8:2572-2576.
9. Panula P., Pirvola U., Auvinen S., et al. Histamine immunoreactive nerve fibers in the rat brain. Neuroscience 1989, 28:585-610.
10. Ericson H., Watanabe T., Kohler C. Morphological analysis of the tuberomammillary nucleus in the rat brain: delineation of subgroups with antibody against L-histidine decarboxylase as a marker. J Comp Neurol 1987, 263:1-24.
11. Brown R.E., Stevens D.R., Haas H.L. The physiology of brain histamine. Prog Neurobiol 2001, 63:637-672.
12. Ibrahim M.Z.M. The mast cells of the mammalian central nervous system. Part 1. Morphology, distribution and histochemistry. J Neurol Sci 1974, 21:431-478.
13. Dimiditriadou V., Lambracht-Hall M., Reichler J., et al. Histochemical and ultrastructural characteristics of rat brain perivascular mast cells stimulated with compound 48/80 and carbachol. Neuroscience 1990, 39:209-224.
14. Khalil M., Ronda J., Weintraub M., et al. Brain mast cell relationship to neurovasculature during development. Brain Res 2007, 1171:18-29.
15. Gruber B.L., Marchese M.J., Kew R. Angiogenic factors stimulate mast-cell migration. Blood 1995, 86:2488-2493.
16. Taylor A.M., Galli S.J., Coleman J.W. Stem-cell factor, the kit ligand, induces direct degranulation of rat peritoneal mast cells invitro and invivo: dependence of the invitro effect on period of culture and comparisons of stem-cell factor with other mast cell-activating agents. Immunology 1995, 86:427-433.
17. Halova I., Draberova L., Draber P. Mast cell chemotaxis-chemoattractants and signaling pathways. Front Immunol 2012, 3:119.
18. Katoh Y., Niimi M., Yamamoto Y., et al. Histamine production by cultured microglial cells of the mouse. Neurosci Lett 2001, 305:181-184.
19. Yamakami J., Sakurai E., Kuramasu A., et al. L-Histidine decarboxylase protein and activity in rat brain micro-vascular endothelial cells. Inflamm Res 2000, 49:231-235.
20. Deli M.A., Ábrahám C.S. Histamine and the blood-brain barrier. Histamine: Biology and Medical Aspects 2004, 264-271. SpringerMed Publishing-Karger, Budapest. A. Falus, N. Grossman, D. Zs (Eds.).
21. Wada H., Inagaki N., Itowi N., et al. Histaminergic neuron system in the brain: distribution and possible functions. Brain Res Bull 1991, 27:367-370.
22. Haas H.L., Seergeva O.A., Selbach O. Histamine in the nervous system. Physiol Rev 2008, 88:1183-1241.
23. Ferreira R., Santos T., Gonçalves J., et al. Histamine modulates microglia function. J Neuroinflammation 2012, 9:90.
24. Dong H., Zhang W., Zeng X., et al. Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia. Mol Neurobiol 2014, 49:1487-1500.
25. Rocha S.M., Pires J., Steves M., et al. Histamine: a new immunomodulatory player in the neuron-glia crosstalk. FNCEL 2014, 8:120.
26. Hough L.B. Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 2001, 59:415-419.
27. Hill S.J. Distribution, properties, and functional characteristics of three classes of histamine receptors. Pharmacol Rev 1990, 42:45-83.
28. Haas H., Panula P. The role of histamine and the tuberomammillary nucleus in the nervous system. Nat Rev Neurosci 2003, 4:121-130.
29. Parsons M.E., Ganellin C.R. Histamine and its receptors. Br J Pharmacol 2006, 147:127-135.
30. Arrang J.M., Garbarg M., Schwartz J.C. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983, 302:832-837.
31. Lovenberg T.W., Roland B.L., Wilson S.J., et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999, 55:1101-1107.
32. Schwartz J.C., Arrang J.M., Garbarg M., et al. Modulation of histamine synthesis and release in brain via presynaptic autoreceptors and heteroreceptors. Ann NY Acad Sci 1990, 604:40-54.
33. Schlicker E., Kathmann M., Detzner M., et al. H3 receptor-mediated inhibition of noradrenaline release: an investigation into the involvement of Ca2+ and K+ ions, G protein and adenylate cyclase. Naunyn Schmiedebergs Arch Pharmacol 1994, 350:34-41.
34. Pillot C., Heron A., Cochois V., et al. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 2002, 114:173-193.
35. Arrang J.M., Morisset S., Gbahou F. Constitutive activity of the histamine H3 receptor. Trends Pharmacol Sci 2007, 28:350-357.
36. O'Reilly M., Alpert R., Jenkinson S., et al. Identification of a histamine H4 receptor on human eosinophils-role in eosinophil chemotaxis. J Recept Signal Transduct Res 2002, 22:431-448.
37. De Esch I.J., Thurmond R.L., Jongejan A., et al. The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 2005, 26:462-469.
38. Thurmond R.L., Gelfand E.W., Dunford P.J. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008, 7:41-53.
39. Connelly W.M., Shenton F.C., Lethbridge N., et al. The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 2009, 157:55-63.
40. Teuscher C., Subramanian M., Noubade R., et al. Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc Natl Acad Sci U S A 2007, 104:10146-10151.
41. Ehrlich P. Das sauerstufbudurfnis des organismus. Eine Farbenanalytische Studie 1885, Hirschwald, Berlin.
42. Goldman EE. Vitalbarfung am Zentralnervensystem: Preuss Akad Wiss1913.
43. Stern L., Peyrot R. Le fonctionement de la barrie're hématoencéphalique aux divers stades de dévelopment chez diverses espe'ces animals. Compt Rendus Séances Soc Biol 1927, 96:1124-1126.
44. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.
45. Wolburg H., Noell S., Mack A., et al. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res 2009, 335:75-96.
46. Nag S., Begley D.J. Blood-brain barrier, exchange of metabolites and gases. Pathology and Genetics. Cerebrovascular Diseases 2005, 22-29. ISN Neuropathology Press, Basel. H. Kalimo (Ed.).
47. Abbott N.J., Patabendige A.A., Dolman D.E., et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010, 37:13-25.
48. Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002, 200:629-638.
49. Abbott N.J., Rönnbäck L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7:41-53.
50. Nadal A., Fuentes E., Pastor J., et al. Plasma albumin is a potent trigger of calcium signals and DNA synthesis in astrocytes. PNAS 1995, 92:1426-1430.
51. Gingrich M.B., Traynelis S.F. Serine proteases and brain damage-is there a link?. Trends Neurosci 2000, 23:399-407.
52. Furuse M. Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol 2010, 2:1-14.
53. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002, 38:323-337.
54. Gonzalez-Mariscal L., Namorado M.C., Martin D., et al. Tight junction proteins ZO-1, ZO-2, and occludin along isolated renal tubules. Kidney Int 2000, 57:2386-2402.
55. Lambracht-Hall M., Dimitriadou V., Theoharides T.C. Migration of mast cells in the developing rat brain. Dev Brain Res 1990, 56:151-159.
56. Maślińska D., Laure-Kamionowska M., Gujski M., et al. Post-infectional distribution and phenotype of mast cells penetrating human brains. Inflamm Res 2005, 54(Suppl 1):15-16.
57. Esposito P., Gheorghe D., Kandere K., et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001, 888:117-127.
58. Lindsberg P.J., Strbian D., Karjalainen-Lindsberg M.L. Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J Cereb Blood Flow Metab 2010, 30:689-702.
59. Biran V., Cochois V., Karroubi A., et al. Stroke induces histamine accumulation and mast cell degranulation in the neonatal rat brain. Brain Pathol 2008, 18:1-9.
60. Shimada R., Nakao K., Furutani R., et al. A rat model of changes in dural mast cells and brain histamine receptor H3 expression following traumatic brain injury. J Clin Neurosci 2012, 19:447-451.
61. Jin Y., Silverman A.J., Vannucci S.J. Mast cells are early responders after hypoxia-ischemia in immature rat brain. Stroke 2009, 40:3107-3112.
62. Stanimirovic D., Satoh K. Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation. Brain Pathol 2000, 10:113-126.
63. Deli M.A., Dehouck M.P., Cecchelli R., et al. Histamine induces a selective albumin permeation through the blood-brain barrier invitro. Inflamm Res 1995, 44:56-57.
64. Joó F. The role of histamine in brain oedema formation. Funct Neurol 1993, 8:243-250.
65. Yang Y., Estrada E.Y., Thompson J.F., et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007, 27:697-709.
66. Mattila O.S., Strbian D., Saksi J., et al. Cerebral mast cells mediate blood-brain barrier disruption in acute experimental ischemic stroke through perivascular gelatinase activation. Stroke 2011, 42:3600-3605.
67. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
68. Jackson J.R., Seed M.P., Kircher C.H., et al. The codependence of angiogenesis and chronic inflammation. FASEB J 1997, 11:457-465.
69. Winkler J.D., Jackson J.R. Chronic inflammation and angiogenesis. Angiogenesis in Health and Disease: Basic Mechanisms and Clinical Applications 2000, 407-416. Marcel Dekker, New York. G.M. Rubanyi (Ed.).
70. Kirk S.L., Karlik S.J. VEGF and vascular changes in chronic neuroinflammation. J Autoimmun 2003, 21:353-363.
71. Kempuraj D., Asadi S., Zhang B., et al. Mercury induces inflammatory mediator release from human mast cells. J Neuroinflamm 2010, 7:20.
72. Rigau V., Morin M., Rousset M.C., et al. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 2007, 130:1942-1956.
73. Croll S.D., Goodman J.H., Scharfman H.E. Vascular endothelial growth factor (VEGF) in seizures: a double-edged sword. Adv Exp Med Biol 2004, 548:57-68.
74. Newton S.S., Girgenti M.J., Collier E.F., et al. Electroconvulsive seizure increases adult hippocampal angiogenesis in rats. Eur J Neurosci 2006, 24:819-828.
75. Nicoletti J.N., Shah S.K., McCloskey D.P., et al. Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus. Neuroscience 2008, 151:232-241.
76. Aly H., Khashaba M.T., El-Ayouty M., et al. IL-1beta, IL-6 and TNF-alpha and outcomes of neonatal hypoxic ischemic encephalopathy. Brain Dev 2006, 28:178-182.
77. Megyeri P., Abrahám C.S., Temesvári P., et al. Recombinant human tumor necrosis factor alpha constricts pial arterioles and increases blood-brain barrier permeability in newborn piglets. Neurosci Lett 1992, 148:137-140.
78. Wiggins-Dohlvik K., Merriman M., Shaji C.A., et al. Tumor necrosis factor-α disruption of brain endothelial cell barrier is mediated through matrix metalloproteinase-9. Am J Surg 2014, 208:954-960.
79. Beattie E.C., Stellwagen D., Morishita W., et al. Control of synaptic strength by glial TNFalpha. Science 2002, 295:2282-2285.
80. Stellwagen D., Beattie E.C., Seo J.Y., et al. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005, 25:3219-3228.
81. Pribiag H., Stellwagen D. TNF-α downregulates inhibitory neurotransmission through protein phosphatase 1-dependent trafficking of GABA(A) receptors. J Neurosci 2013, 33:15879-15893.
82. Löscher W. Mechanisms of drug resistance in status epilepticus. Epilepsia 2007, 48:74-77.
83. Joshi S., Kapur J. GABAA receptor plasticity during status epilepticus. Jasper's Basic Mechanisms of the Epilepsies 2012, 1-12. National Center for Biotechnology Information (US), Bethesda, MD. 4th ed. J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta (Eds.).
84. Marchi N., Teng Q., Nguyen M.T., et al. Multimodal investigations of trans-endothelial cell trafficking under condition of disrupted blood-brain barrier integrity. BMC Neurosci 2010, 11:34.
85. Janigro D. Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier. Epilepsia 2012, 53:26-34.
86. Ivens S., Kaufer D., Flores L.P., et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 2007, 130:535-547.
87. David Y., Cacheaux L.P., Ivens S., et al. Astrocytic dysfunction in epileptogenesis: consequence of altered potassium and glutamate homeostasis?. J Neurosci 2009, 29:10588-10599.
88. Aronica E., Crino P.B. Inflammation in epilepsy: clinical observations. Epilepsia 2011, 52(Suppl 3):26-32.
89. Hirsch E.C., Vyas S., Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 2012, 18(Suppl 1):210-212.
90. González H., Elgueta D., Montoya A., et al. Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol 2014, 274:1-13.
91. Najjar S., Pearlman D.M. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res 2015, 161:102-112.
92. Takeda S., Sato N., Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front Aging Neurosci 2014, 6:1-8.
93. Theoharides T.C., Cochrane D.E. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004, 146:1-12.
94. Strbian D., Karjalainen-Lindsberg M.L., Tatlisumak T., et al. Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab 2006, 26:605-612.
95. Nelissen S., Lemmens E., Geurts N., et al. The role of mast cells in neuroinflammation. Acta Neuropathol 2013, 125:637-650.
96. Elices M.J. Neuroinflammatory diseases and the importance of a healthy blood-brain barrier. Curr Opin Investig Drugs 2008, 9:1149-1150.
97. Niederhoffer N., Levy R., Sick E., et al. Amyloid beta peptides trigger CD47-dependent mast cell secretory and phagocytic responses. Int J Immunopathol Pharmacol 2009, 22:473-483.
98. Maslinska D., Laure-Kamionowska M., Maslinski K.T., et al. Distribution of tryptase-containing mast cells and metallothionein reactive astrocytes in human brains with amyloid deposits. Inflamm Res 2007, 56(Suppl 1):S17-S18.
99. Piette F., Belmin J., Vincent H., et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 2011, 3:16.
100. Tunçel N., Sener E., Cerit C., et al. Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy. Peptides 2005, 26:827-836.
101. Korkmaz O.T., Tunçel N., Tunçel M., et al. Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells. J Mol Neurosci 2010, 41:278-287.
102. Seol I.W., Kuo N.Y., Kim K.M. Effects of dopaminergic drugs on the mast cell degranulation and nitric oxide generation in RAW 264.7 cells. Arch Pharm Res 2004, 27:94-98.
103. Strbian D., Karjalainen-Lindsberg M.L., Kovanen P.T., et al. Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation 2007, 116:411-418.
104. Tósaki A., Szerdahelyi P., Joó F. Treatment with ranitidine of ischemic brain edema. Eur J Pharmacol 1994, 264:455-458.
105. Malagelada C., Xifró X., Badiola N., et al. Histamine H2-receptor antagonist ranitidine protects against neural death induced by oxygen-glucose deprivation. Stroke 2004, 35:2396-2401.
106. Rozniecki J.J., Hauser S.L., Stein M., et al. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 1995, 37:63-66.
107. Ibrahim M.Z., Reder A.T., Lawand R., et al. The mast cells of the multiple sclerosis brain. J Neuroimmunol 1996, 70:131-138.
108. Kallweit U., Aritake K., Bassetti C.L., et al. Elevated CSF histamine levels in multiple sclerosis patients. Fluids Barriers CNS 2013, 10:19.
109. Hong G.U., Kim N.G., Jeoung D., et al. Anti-CD40 Ab- or 8-oxo-dG-enhanced Treg cells reduce development of experimental autoimmune encephalomyelitis via down-regulating migration and activation of mast cells. J Neuroimmunol 2013, 260:60-73.
110. Theoharides T.C., Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004, 25:235-241.
111. Põlajeva J., Sjösten A.M., Lager N., et al. Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12. PLoS One 2011, 6:e25222.
112. Theoharides T.C., Rozniecki J.J., Sahagian G., et al. Impact of stress and mast cells on brain metastases. Neuroimmunology 2008, 205:1-7.
113. Lassman A.B., DeAngelis L.M. Brain metastases. Neurol Clin 2003, 21:1-23. vii.
114. Moura D.S., Sultan S., Georgin-Lavialle S., et al. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PLoS One 2011, 6:e26375.
115. Gurgel J.A., Lima-Júnior R.C., Rabelo C.O., et al. Amitriptyline, clomipramine, and maprotiline attenuate the inflammatory response by inhibiting neutrophil migration and mast cell degranulation. Rev Bras Psiquiatr 2013, 35:387-392.
116. Yuzurihara M., Ikarashi Y., Ishige A., et al. Effects of drugs acting as histamine releasers or histamine receptor blockers on an experimental anxiety model in mice. Pharmacol Biochem Behav 2000, 67:145-150.
117. Nautiyal K.M., Ribeiro A.C., Pfaff D.W., et al. Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci U S A 2008, 105:18053-18057.
118. Chikahisa S., Kodama T., Soya A., et al. Histamine from brain resident MAST cells promotes wakefulness and modulates behavioral states. PLoS One 2013, 8:e78434.
119. Janigro D., Iffland P.H., Marchi N., et al. A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia 2013, 54(Suppl 6):30-32.
120. Allan S.M., Rothwell N.J. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001, 2:734-744.
121. De Simoni M.G., Perego C., Ravizza T., et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci 2000, 12:2623-2633.
122. Voutsinos-Porche B., Koning E., Kaplan H., et al. Temporal patterns of the cerebral inflammatory response in the rat lithium-pilocarpine model of temporal lobe epilepsy. Neurobiol Dis 2004, 17:385-402.
123. Dhote F., Peinnequin A., Carpentier P., et al. Prolonged inflammatory gene response following soman-induced seizures in mice. Toxicology 2007, 238:166-176.
124. Ravizza T., Gagliardi B., Noe F., et al. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 2008, 29:142-160.
125. Eriksson C., Tehranian R., Iverfeldt K., et al. Increased expression of mRNA encoding interleukin-1beta and caspase-1, and the secreted isoform of interleukin-1 receptor antagonist in the rat brain following systemic kainic acid administration. J Neurosci Res 2000, 60:266-279.
126. Hu S., Sheng W.S., Ehrlich L.C., et al. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation 2000, 7:153-159.
127. Vezzani A., Balosso S., Ravizza T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun 2008, 22:797-803.
128. Vezzani A., French J., Bartfai T., et al. The role of inflammation in epilepsy. Nat Rev Neurol 2011, 7:31-40.
129. Vezzani A., Maroso M., Balosso S., et al. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun 2011, 25:1281-1289.
130. Friedman A. Blood-brain barrier dysfunction, status epilepticus, seizures, and epilepsy: a puzzle of a chicken and egg?. Epilepsia 2011, 52(Suppl 8):19-20.
131. Friedman A., Heinemann U. Role of blood-brain barrier dysfunction in epileptogenesis. Jasper's Basic Mechanisms of the Epilepsies [Internet] 2012, 1-12. National Center for Biotechnology Information (US), Bethesda (MD). 4th ed. J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta (Eds.).
132. Heinemann U., Kaufer D., Friedman A. Blood-brain barrier dysfunction, TGFβ signaling, and astrocyte dysfunction in epilepsy. Glia 2012, 60:1251-1257.
133. Oby E., Janigro D. The blood-brain barrier and epilepsy. Epilepsia 2006, 47:1761-1774.
134. Shlosberg D., Benifla M., Kaufer D., et al. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol 2010, 6:393-403.
135. Gholipoor P., Saboory E., Roshan-Milani S., et al. Effect of hyperthermia on histamine blood level and convulsive behavior in infant rats. Epilepsy Behav 2013, 29:269-274.
136. Bleck T.P. Hypothermia, hyperthermia, and other systemic factors in status epilepticus. Epilepsia 2009, 50(Suppl 12):10.
137. Liu H., Sankar R., Shin D.H., et al. Patterns of status epilepticus-induced substance P expression during development. Neuroscience 2000, 101:297-304.
138. Cocchiara R., Albeggiani G., Lampiasi N., et al. Histamine and tumor necrosis factor-alpha production from purified rat brain mast cells mediated by substance P. Neuroreport 1999, 10:575-578.
139. Elices M.J., Osborn L., Takada Y., et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990, 60:577-584.
140. Meng H., Tonnesen M.G., Marchese M.J., et al. Mast cells are potent regulators of endothelial cell adhesion molecule ICAM-1 and VCAM-1 expression. J Cell Physiol 1995, 165:40-53.
141. Librizzi L., Regondi M.C., Pastori C., et al. Expression of adhesion factors induced by epileptiform activity in the endothelium of the isolated guinea pig brain invitro. Epilepsia 2007, 48:743-751.
142. Fabene P.F., Navarro Mora G., Martinello M., et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med 2008, 14:1377-1383.
143. Duffy B.A., Choy M., Riegler J., et al. Imaging seizure-induced inflammation using an antibody targeted iron oxide contrast agent. Neuroimage 2012, 60:1149-1155.
144. Jung K.H., Chu K., Lee S.T., et al. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol Dis 2006, 23:237-246.
145. Marchi N., Fan Q.Y., Ghosh C., et al. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis 2009, 33:171-181.
146. Zeng L.H., Rensing N.R., Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 2009, 29:6964-6972.
147. Riazi K., Galic M.A., Pittman Q.J. Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability. Epilepsy Res 2010, 89:34-42.
148. Marchi N., Granata T., Freri E., et al. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One 2011, 6:e18200.
149. Ravizza T., Balosso S., Vezzani A. Inflammation and prevention of epileptogenesis. Neurosci Lett 2011, 497:223-230.
150. HJ1 Zhang, Sun R.P., Lei G.F., et al. Cyclooxygenase-2 inhibitor inhibits hippocampal synaptic reorganization in pilocarpine-induced status epilepticus rats. J Zhejiang Univ Sci B 2008, 9:903-915.
151. Gao F., Liu Y., Li X., et al. Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model. Pharmacol Biochem Behav 2012, 103:187-196.
152. Deli M.A., Abrahám C.S., Kataoka Y., et al. Permeability studies on invitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 2005, 25:59-127.
153. Duffy B.A., Chun K.P., Ma D., et al. Dexamethasone exacerbates cerebral edema and brain injury following lithium-pilocarpine induced status epilepticus. Neurobiol Dis 2014, 63:229-236.
154. Stienen M.N., Haghikia A., Dambach H., et al. Anti-inflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGFβ1 regulation. Br J Pharmacol 2011, 162:491-507.
155. Dambach H., Hinkerohe D., Prochnow N., et al. Glia and epilepsy: experimental investigation of antiepileptic drugs in an astroglia/microglia co-culture model of inflammation. Epilepsia 2014, 55:184-192.
156. Gómez C.D., Buijs R.M., Sitges M. The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1β and TNF-α expression in rat hippocampus. J Neurochem 2014, 130:770-779.
157. Suzuki-Nishimura T., Oku N., Nango M., et al. PEI6, a new basic secretagogue in rat peritoneal mast cells: characteristics of polyethylenimine PEI6 resemble those of compound 48/80. Gen Pharmacol 1995, 26:1171-1178.
158. Marone G., Stellato C., Mastronardi P., et al. Mechanisms of activation of human mast cells and basophils by general anesthetic drugs. Ann Fr Anesth Reanim 1993, 12:116-125.
159. Zhuang X., Silverman A.J., Silver R. Brain mast cell degranulation regulates blood-brain barrier. J Neurobiol 1996, 31:393-403.